P. Souverein

发表

Evaluation of Risk Profiles for Gastrointestinal and Cardiovascular Adverse Effects in Nonselective NSAID and COX-2 Inhibitor Users

S. Shakir, A. Egberts, D. Layton, 2008, Drug safety.

Antipsychotic Drug Use and Risk of Pneumonia in Elderly People

A. Egberts, P. Jansen, R. V. van Marum, 2008, Journal of the American Geriatrics Society.

Risk of drug‐induced photosensitivity: focus on spectroscopic and molecular characteristics

R. Meyboom, A. Egberts, H. Leufkens, 2009, Pharmacoepidemiology and Drug Safety.

Changes in medication associated with epilepsy‐related hospitalisation: a case‐crossover study

J. Z. Zwart-van Rijkom, Toine Cornelis Gerardus Egberts, K. B. Handoko, 2007, Pharmacoepidemiology and drug safety.

Risk of Aplastic Anemia in Patients Using Antiepileptic Drugs

R. Meyboom, H. Leufkens, P. M. van den Bemt, 2006, Epilepsia.

Changes in outpatient lithium treatment in the Netherlands during 1996-2005.

W A Nolen, A. Egberts, W. Nolen, 2008, Journal of affective disorders.

The Dutch cohort of sildenafil users: baseline characteristics

J. Urquhart, A. Egberts, P. Souverein, 2001, BJU international.

The Association between Exposure to COX-2 Inhibitors and Schizophrenia Deterioration. A Nested Case-Control Study

A. Egberts, H. Leufkens, H. Leufkens, 2007, Pharmacopsychiatry.

Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study

C. Huerta, R. Gini, C. Giaquinto, 2022, Vaccine.

Drug-Related Nephrotoxic and Ototoxic Reactions

A. Egberts, H. Leufkens, B. Verdel, 2008, Drug safety.

Use of α‐blockers and the risk of hip/femur fractures

C. Cooper, A. Egberts, H. Leufkens, 2003, Journal of internal medicine.

Prescriber adoption of newly approved selective COX‐2 inhibitors

S. Shakir, D. Layton, P. Souverein, 2008, Pharmacoepidemiology and drug safety.

Hospitalisation as a Determinant for Discontinuity of Drug Use

A. Egberts, E. Heerdink, R. Stuffken, 2007 .

Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study

C. Cooper, A. Egberts, P. Souverein, 2004, Heart.

Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia.

P. Souverein, J. Vandenbroucke, O. Dekkers, 2009, The Journal of clinical endocrinology and metabolism.

Microbial evaluation of proton-pump inhibitors and the risk of pneumonia

P. Souverein, H. Leufkens, H. Endeman, 2011, European Respiratory Journal.

Antipsychotic Drug Use and Risk of Pneumonia in Elderly People

A. Egberts, P. Jansen, R. V. van Marum, 2008, Journal of the American Geriatrics Society.

Use of proton pump inhibitors and risk of iron deficiency: a population‐based case–control study

A. Hoes, P. Souverein, N. D. de Wit, 2018, Journal of internal medicine.

High risk of drug‐induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors

P. Souverein, A. Keshavarzian, D. Jonkers, 2016, Alimentary pharmacology & therapeutics.

Combined influence of proton‐pump inhibitors, calcium‐channel blockers and CYP2C19*2 on on‐treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention

P. Souverein, A. de Boer, V. Deneer, 2011, Journal of thrombosis and haemostasis : JTH.

Short‐ and long‐term effects of real‐time medication monitoring with short message service (SMS) reminders for missed doses on the refill adherence of people with Type 2 diabetes: evidence from a randomized controlled trial

P. Souverein, M. Bouvy, M. Vervloet, 2014, Diabetic medicine : a journal of the British Diabetic Association.

A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction

J. Hasford, P. Souverein, R. Reynolds, 2016, European Journal of Clinical Pharmacology.

Discontinuation of statins among patients with type 2 diabetes

P. Souverein, L. Welschen, G. Nijpels, 2012, Diabetes/metabolism research and reviews.

ACCESS-Background rate of adverse events-definition –Single Organ Cutaneous Vasculitis

C. Willame, M. Sturkenboom, P. Souverein, 2021 .

ACCESS-Background rate of adverse events-definition –Acute Kidney Injury

C. Willame, M. Sturkenboom, P. Souverein, 2021 .

ACCESS-Background rate of adverse events-definition –Acute Respiratory Distress Syndrome

M. Sturkenboom, P. Souverein, L. Belbachir, 2021 .

ACCESS-Background rate of adverse events-definition –Anosmia & Ageusia

C. Willame, M. Sturkenboom, P. Souverein, 2021 .

ACCESS-Background rate of adverse events-definition –Heart Failure

C. Huerta, C. Willame, M. Sturkenboom, 2021 .

ACCESS-Background rate of adverse events-definition –Stress Cardiomyopathy

C. Willame, M. Sturkenboom, P. Souverein, 2021 .

ACCESS-Background rate of adverse events-definition –Arrhythmia

C. Willame, M. Sturkenboom, P. Souverein, 2021 .

ACCESS: Background rates of AESI to monitor vaccine safety- GBS definition

C. Willame, M. Sturkenboom, P. Souverein, 2021 .